Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Abbott Medical Devices | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Use of continuous glucose monitor (CGM) in post kidney transplant patients to better assess changes in glucose levels post kidney transplant
This is a non-randomized perspective single arm study with a planned enrollment of 20 patients. The primary objective is to characterize the glucometrics (description of glucose readings in relation to target goals) achieved by a CGM-based insulin titrating protocol for glucocorticoid taper for post kidney transplant patients. The secondary objective is to explore the relationship between the CGM glucometrics and rates of readmission, rejection and delayed graft function in post kidney transplant patients.
A total of 20 patients that are post kidney transplant, will undergo intervention until 3 months post-transplant. Informed consent will be obtained prior to start of study. The final visit will be at 3 months. Patients will be discharged to their local endocrinologist or primary care physician at this 3-month mark. Data will continue to be gathered for 3 more months after exit from intervention. Enrollment will be within the first 2 weeks of hospital discharge. Visits are standard of care (SOC) at the Kidney Transplant Clinic or at the Endocrinology clinic and will be virtual, in-person or telephone encounter.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Post Kidney Transplant, using CGM | A total of 20 patients that are post kidney transplant, will wear a Continuous Glucose Monitor (CGM) until 3 months post-transplant. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Time in Range (TIR) | Percent of patients who achieved Time in Range (55 mg/dL to 180 mg/dL Glucose) as measured by the Continuous Glucose Monitor | 6 months |
| Hospital Readmission | Percent of patients who experienced a hospital readmission | 6 months |
| Time below range (TBR) | Percent of patients who achieved Time below range (<54 mg/dL Glucose) as measured by the Continuous Glucose Monitor | 6 months |
| Time above range (TAR) | Percent of patients who achieved Time above range (181-250mg/dL and >250 mg/dL Glucose) as measured by the Continuous Glucose Monitor | 6 months |
| Rejection | Percent of patients who experienced a rejection of the transplanted kidney | 6 months |
| Delayed graft function | Percent of patients who experienced delayed graft function | 6 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This is a non-randomized prospective single arm study with a planned enrollment of 20 patients.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | United States |
IPD will not be shared due to the disclosure on the consent form for which IRB approval was received. Deidentified summarized results will be shared via publication in a medical journal
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jun 24, 2024 | Nov 26, 2025 | Prot_000.pdf |
Not provided
Not provided
Not provided
Not provided